Elan reports narrower losses
Athlone based pharmaceutical company Elan has reported narrower net losses for the first half of the year, helped by increased revenue from its multiple sclerosis treatment drug Tysabri.
Elan Corp., the Dublin drug maker, swung to a third-quarter profit from a year-earlier loss on 17% higher revenue, and it affirmed its outlook for the full year.